[go: up one dir, main page]

ZA961161B - Medicinal combination for transfecting and expressing exogenous genes in vivo - Google Patents

Medicinal combination for transfecting and expressing exogenous genes in vivo

Info

Publication number
ZA961161B
ZA961161B ZA961161A ZA961161A ZA961161B ZA 961161 B ZA961161 B ZA 961161B ZA 961161 A ZA961161 A ZA 961161A ZA 961161 A ZA961161 A ZA 961161A ZA 961161 B ZA961161 B ZA 961161B
Authority
ZA
South Africa
Prior art keywords
vivo
transfecting
exogenous genes
expressing exogenous
medicinal combination
Prior art date
Application number
ZA961161A
Other languages
English (en)
Inventor
Lucienne Chatenoud
Hedi Haddada
Martin Lee
Michel Perricaudet
Michelle Webb
Jean-Francois Bach
Original Assignee
Inst Nat Sante Rech Med
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Rhone Poulenc Rorer Sa filed Critical Inst Nat Sante Rech Med
Publication of ZA961161B publication Critical patent/ZA961161B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA961161A 1995-02-14 1996-02-13 Medicinal combination for transfecting and expressing exogenous genes in vivo ZA961161B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9501662A FR2730411B1 (fr) 1995-02-14 1995-02-14 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (1)

Publication Number Publication Date
ZA961161B true ZA961161B (en) 1996-08-07

Family

ID=9476106

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA961161A ZA961161B (en) 1995-02-14 1996-02-13 Medicinal combination for transfecting and expressing exogenous genes in vivo

Country Status (23)

Country Link
US (2) US20030004091A1 (xx)
EP (1) EP0809516B1 (xx)
JP (1) JPH11500430A (xx)
KR (1) KR100402540B1 (xx)
AT (1) ATE204481T1 (xx)
AU (1) AU717218B2 (xx)
BR (1) BR9607310A (xx)
CA (1) CA2211039C (xx)
CZ (1) CZ258197A3 (xx)
DE (1) DE69614668T2 (xx)
DK (1) DK0809516T3 (xx)
ES (1) ES2163612T3 (xx)
FI (1) FI119176B (xx)
FR (1) FR2730411B1 (xx)
GR (1) GR3036438T3 (xx)
HU (1) HU222991B1 (xx)
IL (1) IL117116A0 (xx)
MX (1) MX9706017A (xx)
NO (1) NO320072B1 (xx)
PT (1) PT809516E (xx)
SK (1) SK282235B6 (xx)
WO (1) WO1996025177A1 (xx)
ZA (1) ZA961161B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
AU4088697A (en) * 1996-08-26 1998-03-19 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
EP1025242A1 (en) 1997-10-30 2000-08-09 Cornell Research Foundation, Inc. A method of inhibiting an immune response to a recombinant vector
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2000074688A1 (en) * 1999-06-08 2000-12-14 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AU5969101A (en) 2000-05-12 2001-11-26 Genzyme Corp Modulators of tnf-alpha signaling
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
CA2461905A1 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
ES2371635T3 (es) * 2002-11-21 2012-01-05 Genzyme Corporation Combinación de un derivado de diamida y agentes inmunosupresores para inhibir el rechazo de transplantes.
PT1567138E (pt) * 2002-11-21 2011-04-11 Genzyme Corp Utilização de derivados de diamida para inibição de rejeição crónica de transplante
WO2005076965A2 (en) * 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016065A1 (en) * 1992-12-31 1994-07-21 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
AU5965294A (en) * 1993-01-08 1994-08-15 Exemplar Corporation An (in vitro)/(in vivo) method for identifying anti-neoplastic drugs
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus

Also Published As

Publication number Publication date
AU4723896A (en) 1996-09-04
CA2211039A1 (fr) 1996-08-22
FR2730411B1 (fr) 1997-03-28
SK110897A3 (en) 1998-01-14
FI973323A0 (fi) 1997-08-13
NO973724D0 (no) 1997-08-13
FI119176B (fi) 2008-08-29
EP0809516B1 (fr) 2001-08-22
EP0809516A1 (fr) 1997-12-03
FR2730411A1 (fr) 1996-08-14
GR3036438T3 (en) 2001-11-30
NO320072B1 (no) 2005-10-17
PT809516E (pt) 2002-02-28
AU717218B2 (en) 2000-03-23
DE69614668T2 (de) 2002-06-27
SK282235B6 (sk) 2001-12-03
US20040265276A1 (en) 2004-12-30
HU222991B1 (hu) 2004-01-28
CA2211039C (fr) 2011-12-06
ES2163612T3 (es) 2002-02-01
DK0809516T3 (da) 2001-12-17
HUP9800635A2 (hu) 1998-07-28
KR100402540B1 (ko) 2004-05-07
NO973724L (no) 1997-08-13
DE69614668D1 (de) 2001-09-27
FI973323L (fi) 1997-08-13
KR19980702199A (ko) 1998-07-15
IL117116A0 (en) 1996-06-18
WO1996025177A1 (fr) 1996-08-22
US20030004091A1 (en) 2003-01-02
ATE204481T1 (de) 2001-09-15
BR9607310A (pt) 1997-11-25
HUP9800635A3 (en) 2000-12-28
MX9706017A (es) 1997-11-29
JPH11500430A (ja) 1999-01-12
CZ258197A3 (en) 1997-11-12

Similar Documents

Publication Publication Date Title
ZA961161B (en) Medicinal combination for transfecting and expressing exogenous genes in vivo
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
AU9676198A (en) Drug delivery and gene therapy delivery system
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
ZA961484B (en) Dna molecules preparation and use in gene therapy
AU3119095A (en) Surface expression of enzyme in gene directed prodrug therapy
GR3033534T3 (en) Genetic therapy of diseases of the central nervous system with a cell-specific active substance which is dependent on the cell cycle
WO1996027663A3 (en) An antisense transcript associated to tumor cells having a t(14;18) translocation and oligodeoxynucleotides useful in the diagnosis and treatment of said tumor cells
AU716500B2 (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
EP1007717B8 (en) Methods and compositions for cancer therapies using genes encoding interferon-beta
IL117466A0 (en) Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy
AU6346898A (en) Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters
HUP9904201A3 (en) Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent
IL192893A0 (en) Cell-based gene therapy for the pulmonary system
Agrawal Antisense oligonucleotides as gene expression modulators
HK1030555A (en) Combined electroporation and iontophoresis apparatus for drug and gene delivery
AU2298195A (en) An (in vivo) gene expression system